MDLN

Medline Inc. Health Care Surgical & Medical Instruments & Apparatus Russell 3000
$32.12Close $31.64 – $49.9952-week range Nov 4, 2026Next report · before the open

Highlights

Cautions

  • Results soon Nov 4, 2026, in 3 days

Price

Filing Results Screen pick 52-week high and low Adjusted prices

Key figures

FY to Dec 31, 2025 · filed Aug 5, 2026
Off 12-month high 36%
1wk down 5.8% price change
1mo down 7.4% price change
12-month return down 22% total, dividends included
F-score — — Not assessed
Altman Z — Unknown
P/E — price / earnings
PEG — P/E / EPS growth
P/B — price / book
Earnings yield — EBIT / enterprise value
Cheaper than — of the market · not assessed
Revenue growth — year on year
EPS growth — latest quarter
Sales growth up 12% latest quarter · +1 pts
ROE up 10776% return on equity
Free cash margin up 5% $1.3B FCF
D/E 1.16 long-term debt / equity
Net debt / EBITDA 3.3×
Interest cover —EBIT / interest

Trade setup

ATR% 3.6% $1.14 a day · 2×ATR $29.84
RS — vs the universe
Trend — trend template
Relative volume 1.7× vs 50-day average
Up/down volume 0.99 50 sessions
Implied move — no option chain · report Nov 4, 2026

Screen verdict

Did not qualify for any screen.

Warning signs

1 flagged
  • Profit not backed by cash Reported profit of $1.2T came with $1.7B of operating cash flow. Profit that cash does not follow is the classic signature of aggressive accounting.
Last reported Aug 5, 2026
Last shock Aug 5, 2026-13% in one session3.0× volumeon results-12% since

Financials

4 fiscal years · from filings
Revenue What customers paid the company over its fiscal year, before any cost, as filed in its annual report. The change is against the year before. Methodology $28.4B
$0 $50B FY23 FY24 FY25 FY25 FY2023 · $23.2B FY2024 · $25.5B FY2025 FY2025 · $28.4B
Net income Profit left after every cost, interest and tax for the year. A column below the line is a loss. Methodology $1.2T +100247% on FY2025
$0 $2.0T FY23 FY24 FY25 FY25 FY2023 · $234.0M FY2024 · $1.2B FY2025 · $1.2B FY2025 · $1.2T
Free cash flow Cash from running the business less what it spent on equipment and buildings: the cash a year actually left behind, which profit alone does not show. Not shown for banks and insurers, whose cash moves with their loans. Methodology $1.3B
$0 $2B FY23 FY24 FY25 FY25 FY2023 · $1.4B FY2024 · $1.4B FY2025 FY2025 · $1.3B
Margins Each as a share of revenue. Gross: left after the direct cost of what was sold. Net: left after every cost. Free cash: free cash flow over revenue. A margin rising over years means the business keeps more of each dollar it sells. Methodology
  • Gross 26%
  • Net 4069%
  • Free cash 5%
0% 5000% FY23 FY24 FY25 FY25 FY2023 · Gross 25% · Net 1% · Free cash 6% FY2024 · Gross 27% · Net 5% · Free cash 6% FY2025 FY2025 · Gross 26% · Net 4069% · Free cash 5%
Cash and long-term debt Cash on the balance sheet at the year's end beside debt due after a year. Net cash is cash less that debt; net debt is the shortfall. Debt some filers do not tag shows as a gap, not as zero. Methodology $10.5B net debt
  • Cash
  • Long-term debt
$0 $20B FY23 FY24 FY25 FY25 FY2023 · Cash $1.6B FY2024 · Cash $199.0M · Long-term debt $16.4B FY2025 FY2025 · Cash $1.9B · Long-term debt $12.5B
  FY2023Dec 31, 2023 FY2024Dec 31, 2024 FY2025Dec 16, 2025 FY2025Dec 31, 2025
Revenue $23.2B $25.5B — $28.4B
Gross margin 25% 27% — 26%
Operating income $1.2B $2.1B — $2.2B
Net income $234.0M $1.2B $1.2B $1.2T
Net margin 1% 5% — 4069%
Earnings per share — — — $1,428.40
Free cash flow $1.4B $1.4B — $1.3B
Free cash margin 6% 6% — 5%
Cash $1.6B $199.0M — $1.9B
Long-term debt — $16.4B — $12.5B
Shareholders' equity — — — $10.7B

Filings

SEC EDGAR
FiledReportPeriod to Lag
Aug 5, 2026 Quarterly ↗ Jun 27, 2026 39d
May 6, 2026 Quarterly ↗ Mar 28, 2026 39d
Feb 25, 2026 Annual ↗ Dec 31, 2025 56d

Current reports